VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
XSTEM-VLU
Preclinical
Biologic
X
Xintela AB
1
Indications
1
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Venous Leg Ulcer
Completed
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Venous Leg Ulcer
Preclinical
Completed
Clinical
Trials by Indication
[1]
Venous Leg Ulcer
1 trial
A Multi-centre, Randomised, Single-blind Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of a Single Topical Dose of Allogeneic Integrin α10β1-selected Mesenchymal Stem Cells (XSTEM-VLU) in Patients With Difficult-to-heal Venous Leg Ulcers
Completed
·
X
Xintela AB
·
Preclinical
·
NCT05549609
·
6 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for XSTEM-VLU. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
XSTEM-VLU compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for XSTEM-VLU. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Xintela AB company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Biologic
[2]
Highest Phase
Preclinical
[1]
Company
X
Xintela AB
Related News